Antidiabetic Flashcards

1
Q

Adrenergic α2

A

receptor activation decreases insulin release (predominant) by inhibiting β-cell adenylyl cyclase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Adrenergic β2

A

stimulation increases insulin release (less dominant) by activating β-cell adenylyl cyclase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Vagal stimulation

A

causes insulin secretion through IP3/DAG- increased intracellular Ca2+ in the β-cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Insulin receptor

A

Two α-subunits and two β-subunits. Insulin binds to α-subunit

Activates Tyrosine Kinase → Phosphorylation of tyrosine in β-subunit

Activates insulin receptor substrate (IRS)

Translocation of glucose transporters to cell membrane – increases Glucose uptake into the cells,

Increases glycogen synthesis,
Alters protein and fat metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Actions of Insulin on the liver

A

Inhibits gluconeogenesis (glucose production from protein, pyruvate, FFA and glycerol) and increases glycolysis

Inhibits glycogenolysis and stimulates glycogen synthesis (glycogenesis)

Increases the synthesis of triglycerides

Increases protein synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Overall effects of insulin

A

Overall effects of insulin: to favor storage of fuel
Insulin promotes cellular K+ uptake**

Synthesis of proteins and fats (anabolic)

In the absence of insulin, most body cells cannot take up glucose.

Proteins and fats are broken down to provide energy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Actions of Insulin on the muscle

A

Increases glucose transport and glycolysis
Increases glycogen deposition
Increases protein synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Actions of insulin on adipose tissue

A

Increases glucose transport
Increases triglyceride synthesis (lipogenesis)
Decreases intracellular lipolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Rapid, intermediate & major long term effects

A

Most of the metabolic actions of insulin are exerted within seconds or minutes (rapid actions)

Others involving DNA mediated protein synthesis have a latency of few hours (intermediate actions)

In addition, insulin exerts major long term effects on multiplication and differentiation of cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Is insulin orally active

A

Insulin is orally not active as degraded in the GIT

Insulin is inactivated by insulinase found mainly in kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sources of insulin

A
Beef pancreas (bovine insulin): different from human insulin by 3 Amino acids: allergy concerns  
Associated with a risk of“mad-cow”disease 

Pork pancreas (porcine insulin)- differs from human insulin by 1 Amino acids: allergy concerns less than bovine insulin

Human insulin: recombinant DNA technology: Now commonly used
Human insulin differs from bovine insulin by 3 AA and from porcine insulin by 1 AA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How is human insulin produced

A

Produced by recombinant DNA technology in bacteria (E. coli) and in yeast, or by enzymatic modification of porcine insulin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Advantages of Human insulin

A

Diminished antibody (less chance of insulin resistance)
Less allergic reactions
Less lipodystrophy (insulin is lipogenic – could get swelling of subcutaneous fat at the sites of injection)
During surgery or infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Regular Insulin

A

(Crystalline Zinc Insulin/Soluble Insulin)
Onset is ≥30 mins, duration of action 6-8 hours;
Regular insulin can be given SC, or IV
intravenous (IV) route (for DKA, during surgery or acute infections)
Need to wait for 30 min to have meals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Short acting insulin analogues

A

Insulin Lispro, Insulin Aspart and Insulin Glulisine: Rapid acting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Characteristics of short acting insulin analogues

A

more rapidly absorbed from subcutaneous sites than regular insulin

Rapid onset within 15 min & duration <3-4 hours;

Meals can be taken within 15 min following injection
more closely mimic normal endogenous prandial insulin secretion than does regular insulin

have the lowest variability of absorption (from s.c. sites) (approx- 5%) of all available commercial insulin

preferred insulin for use in continuous subcutaneous insulin infusion devices

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Intermediate acting insulin

A

NPH (Neutral Protamine Hagedorn, Isophane) and Lente insulin

Duration of action~ 12-24 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Long acting insulin

A

only s.c.

Ultralente, Insulin glargine, Insulin detemir, Protamine-zinc insulin, Insulin degludec

Duration of action ~ 30 hours, Insulin degludec -40 h

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Split-mixed regimen

A

Calculated daily dose of insulin is split in 2 or 3 doses; and insulin preparations used are of mixed types (short-acting+ intermediate acting (30:70, 50:50 etc) or short-acting+ longer-acting, etc)

Frequently used

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Insulin dosing for standard treatment

A

injection of both short and intermediate acting insulin twice a day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Insulin dosing - Intensive treatment

A

Intensive treatment methods are employed which involve multiple injections:

Multiple regular + intermediate acting insulin injections (in response to monitoring blood glucose levels)

Intensive therapy is not recommended in pts with advanced age and those with hypoglycemic unawareness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Theraputic uses of insulin

A
Diabetes mellitus (Type 1)****
Diabetes mellitus: Type 2: Sometimes, if not well-controlled. Most type 2 diabetics are treated with dietary changes, reduction in body weight, appropriate exercises and oral antidiabetic agents
Diabetic Ketoacidosis (Diabetic coma)****
Hyperosmolar (nonketotic hyperglycemic) coma***

Gestational diabetes**

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

DKA clinical features

A
  • Nausea and vomiting,
  • Abdominal pain
  • Dehydration
  • Tachycardia
  • Hyperventilation – from acidosis
  • Hypotension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

6 steps to DKA management

A
  1. Insulin: Regular insulin IV (bolus + infusion)
    After patient becomes fully conscious, maintenance with s.c. inj
  2. IV fluids***: to correct dehydration- Normal saline (0.9% NaCl)

After blood glucose has reached 300 mg/dl, 5% glucose in ½ N saline is the most appropriate solution

glucose is needed to restore the depleted hepatic glycogen

  1. KCl
    Acidosis causes loss of K+ in urine
    Additionally, when insulin therapy is instituted K+ is driven intracellularly- leading to severe hypokalemia
  2. NaHCO3
    Not routinely needed, because acidosis subsides as ketosis is controlled
  3. Phosphate: (routine use controversial)
  4. Antibiotics: if required; respiratory infections reported in patients developing ketoacidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Hyperosmolae nonketoic hyperglycemic coma

A
  • Usually occurs in elderly type 2 diabetes
  • General principle of treatment are same as for DKA, except that faster fluid replacement is to be instituted and NaHCO3 is usually not required.
  • Patients are prone to thrombosis (due to hyperviscosity and sluggish circulation), prophylactic heparin therapy is recommended (along with insulin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

ADR of Isulin

A

Hypoglycemia**
symptoms: sweating, anxiety, palpitation, tremor, dizziness, headache, behavioral changes, visual disturbances, fatigue, weakness, muscular in-coordination, etc → ultimately coma

Most frequent and the most serious reaction
Can occur in any diabetic pt.
Following inadvertent large doses of insulin injection, or by missing a meal or by performing a vigorous exercise

generally, the reflex sympathetic symptoms occur before the neuroglucopenic symptoms

diabetic neuropathy can abolish the autonomic symptoms***

when blood glucose falls further (< 40 mg/dl) mental confusion, seizures and coma occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

S/S of hypoglycemia are related to

A
counter regulatory sympathetic stimulation- sweating, anxiety, palpitation, tremors 
neuroglucopenic symptoms (due to deprivation of brain of its essential nutrient- glucose)- dizziness, headache, behavioral changes, visual disturbances, fatigue, weakness, muscular incoordination, etc → convulsion and ultimately coma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Hypoglycemia treatment

A

Glucose (sugar candy, sugar syrup etc) must be given orally or IV (10% dextrose for severe cases); reverse the symptoms rapidly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Somogyi effect

A

Blood glucose level drops too low in the midnight hours (Very early morning) due to usage of too much long acting or medium acting insulin at the night before or not eating a snack before bed time.

Released hormones (growth hormone, cortisol, and catecholamines) help to reverse the low blood glucose level but higher than normal in the morning.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Other insulin ADR

A

sensation: Lipodystrophy (lipoatrophy or lipohypertrophy) of subcutaneous fat at the injection site (less seen with new preparations)

Allergic reactions (Anaphylactoid reactions): due to contaminating proteins added to insulin in its formulation (protamine, etc) (very rare with human/highly purified insulins)

Weight gain (insulin is anabolic)

Hypokalemia (uptake of K+ into cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

How do beta blockers prolong hypoglycemia

A

hypoglycemia by inhibiting compensatory mechanisms operating through β2 receptors (β1 selective are less liable).
Additionally, warning signs of hypoglycemia like palpitation, sweating, tremors and anxiety are masked

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

How does alcohol affect hypoglycemia

A

can precipitate hypoglycemia by inhibiting gluconeogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Thiazides, Furosemide, corticosteroids, OCPs, Albuterol, effect on insulin

A

tend to raise blood glucose and reduce effectiveness of insulin

34
Q

Acute insulin resistance

A

develops rapidly and is usually a short term problem.

Causes:
infection, trauma, surgery, stress;
corticosteroids and other hyperglycemic hormones (e.g., Epinephrine) produced in excess during stress—–oppose insulin action

35
Q

Chronic insulin resistance

A

conventional preparations of bovine or porcine insulin

  • Antibodies are formed against insulin
  • Treatment is to switch over to human insulin
36
Q

What are some conditions that are associated with insulin resistance

A

Pregnancy, metabolic syndrome, acromegaly, Cushing’s syndrome, pheocromocytoma, use of oral contraceptives, corticosteroids are associated with insulin resistance

37
Q

Administration of insulin by pump

A

delivers continuous subcutaneous insulin infusion (CSII)
does not need multiple injections during the day

The pump is programmed to deliver basal rate of daily injection of insulin and also allows the patient to control the delivery of a bolus dose of insulin to compensate for high glucose level or in anticipation of postprandial, stress or exercise needs

The type of insulin that is used in the pump is only rapid acting

38
Q

Insulin secretagogues

A

Sulfonylureas: Glyburide, Glipizide, Glimepiride, Gliclazide, Meglitinides (Glinides): Repaglinide, Nateglinide

39
Q

Insulin sensitizers

A

Biguanides

Thiazolidinediones (glitazones)

40
Q

alpha glucosidase inhibitors

A

inhibits glucose absoption

41
Q

incretin based agents

A

GLP-1 analogs

Dipeptidyl peptidase-4 (DPP-4) inhibitors

42
Q

First generation sulfonylureas

A

Chlorpropamide
Tolazamide
Tolbutamide

43
Q

Second generation sulfonylureas

A

Glimepiride
Gliclazide
Glipizide
Glyburide (Glibenclamide)

Second generations are more potent, more efficacious and cause fewer adverse effects.

44
Q

MOA of sulfonylureas

A

These drugs promote insulin release from β-cells of pancreas

Sulfonylureas bind to the SUR-1 subunit of sulfonylurea receptor on the intracellular portion of ATP sensitive K+ channels in β- cells and inhibit K+ efflux

The depolarization resulting from the closed K+ channels facilitates entry of Ca2+ into the cell.

Increase in intracellular Ca2+ level leads to Exocytosis and release of insulin from stored insulin vesicles inside the β- cells of pancreas

45
Q

Sulfonylureas theraputic uses

A

To control hyperglycemia in patients with type 2 DM (not in type 1 DM) who cannot achieve appropriate control with changes in diet/exercise.

Sulfonylureas require some islet function to produce effect, hence not effective in type 1 DM.

Should not be used in patients with renal or liver diseases

46
Q

Sulfonylureas ADR

A

More with first generation, less with second generation

Hypoglycemia*****
more common, can be severe, particularly in elderly with impaired hepatic or renal functions who are taking longer acting sulfonylureas (chlorpropamide, glimepiride)

less with Tolbutamide due to low potency and short duration of action
Secondary failure

Nausea, vomiting
Weight gain (moderate)****
Cholestatic jaundice
Hypersensitivity
Aplastic and hemolytic anemias
Intolerance to alcohol &amp; disulfiram like reaction, (esp first-generation OHAs, particularly with chlorpropamide) 

Cross placenta → fetal hypoglycemia: can deplete insulin from the fetal pancreas; therefore pregnant women with diabetes should be treated with insulin***)

47
Q

Sulfonylureas pharmacokinetics

A

all are well absorbed after oral administration

should be given 30 mins before meal

largely bound (90-99%) to plasma protein

hypoglycemic effects of all sulfonylureas are evident for 12-24 hours

metabolized by the liver, and excreted in urine

48
Q

Selection of sulfonylureas

A

depends upon duration of action, patients age, renal function and adverse effects

Long-acting sulfonylureas, e.g., Glyburide (Glibenclamide), are associated with a greater risk of hypoglycemia- hence should be avoided in the elderly

For elderly, shorter acting sulfonylureas, e.g., tolbutamide should be used

In patients with impaired renal function, glipizide or tolbutamide are preferred since they are not excreted by kidneys

49
Q

Hypoglycemic effects of sulfonylureas

A

Decreased hepatic metabolism or renal excretion: Androgens, Anticoagulants, Azole antifungals, Allopurinol, MAOIs, Chloramphenicol, Clarithromycin, Tricyclic antidepressants, probenecid

Displacement of sulfonylureas from binding proteins:
Sulfonamides, Salicylates, Clofibrate

Hypoglycemic effects of Sulfonylureas are reduced by increased hepatic metabolism or renal excretion of sulfonylureas or by decreased insulin secretion:
Atypical antipsychotics, corticosteroids, β-blockers, Thiazide Diuretics, Niacin, Diazoxide, Rifampin, cholestyramine, phenytoin, sympathomimetics and urinary alkalinizers

50
Q

Meglitinide analog (Repaglinide, Nateglinide)

A

Like sulfonylureas, act by blocking ATP-sensitive K+ channels and increase the release of insulin from pancreatic β-cells

have a fast onset of action, with a peak concentration and peak effect within 1 hour after ingestion.

Metabolized by the liver and should not be used in patients with hepatic insufficiency

Lack sulfur in their structures and may be used in type 2 diabetics with sulfur or sulfonylurea allergies

51
Q

Meglitinide analog (Repaglinide, Nateglinide)

A

Like sulfonylureas, act by blocking ATP-sensitive K+ channels and increase the release of insulin from pancreatic β-cells

have a fast onset of action, with a peak concentration and peak effect within 1 hour after ingestion.

Metabolized by the liver and should not be used in patients with hepatic insufficiency

Lack sulfur in their structures and may be used in type 2 diabetics with sulfur or sulfonylurea allergies

52
Q

Meglitinides are used in combo with?
Should not be used with?
Categorized as what kind of regulator?

A

They are used in combination with metformin or glitazones, (combination therapy has been shown to be more effective than monotherapy of these agents alone)

They should NOT be used along with sulfonylureas due to overlapping mechanism of action

Particularly effective in early release of insulin that occurs after a meal and thus are categorized as postprandial glucose regulators

53
Q

Meglitinides ADR

A

Hypoglycemia (major), Weight gain

Secondary failure

54
Q

Biguanides: Metformin mechanism

A

Activation of AMP-activated protein kinase (AMPK)
↓ hepatic glucose production
↑ glucose uptake and glycolysis
↓ glucose absorption from intestine
↑ peripheral (liver, muscle and fat) insulin sensitivity

55
Q

Biguanides Metformin - Uses

A

given alone or in combination with other antidiabetic drugs in type 2 DM (in obese patient)***

also found useful in the t/t of Polycystic Ovary Syndrome (PCOS) (lowers insulin resistance and can restore normal menstrual cycles and ovulation)

56
Q

Advantages of Metformin to Sulfonylureas

A

causes modest weight loss (due to anorexia).

does not cause hypoglycemia*** (also termed as ‘euglycemic’ agent).

has prominent favorable effect on lipids, producing a significant reduction in serum TG and LDL cholesterol, and an elevation in HDL cholesterol

has potential to prevent macrovascular as well as microvascular complications **of diabetes

57
Q

Metformin ADR

A

GI disturbances: metallic taste, anorexia, nausea, vomiting, diarrhea and abdominal pain.

Risk of lactic acidosis***: Serious and potentially fatal condition; especially in patients with kidney or liver impairment.

Alcohol ingestion can precipitate severe lactic acidosis
Vit. B12 deficiency (rare)

58
Q

Metformin Contraindications

A

Renal and/or hepatic disease
History of lactic acidosis due to any reason
Uncompensated cardiac failure (CHF)
Chronic hypoxic lung disease

59
Q

Thiazolidinediones class

A

Insulin sensitizer

Pioglitazone, Rosiglitazone

60
Q

Thiazolidinediones Mechanism

A

Bind to and activate nuclear receptor (Peroxisome Proliferator Activated Receptor- Gamma ( PPAR-γ)***-

↓ Hepatic glucose production
↑ hepatic glucose uptake
↑ GLUT4 glucose transporters
↑insulin sensitivity in adipose tissue, liver and skeletal muscle

Pioglitazone, Rosiglitazone

61
Q

Thiazolidinediones ADR

A

Hepatotoxicity (Troglitazone- no longer used)

Cardiovascular toxicities: fluid retention-increased risk of MI and CHF.

Heart failure on long term use: Contraindicated in NYHA class III and IV cardiac status

Edema
Weight gain**
Increased risk of bladder cancer with high doses and long-term use of pioglitazone (removed from Europe).

62
Q
Thiazolidinediones used to treat?
Cause reduction in?
Requires the presence of?
Can be given alone or with?
Beneficial effects on serum?
A

Used to treat type-2 diabetes

Cause reduction in HbA1c of 0.5-1.4%

require the presence of insulin

Can be given alone or with metformin or a sulfonylurea

Combination of a Glitazone and metformin - no hypoglycemia

Beneficial effects on serum lipid levels – decrease TG

63
Q

Inhibitors of glucose absorption

A

Acarbose and miglitol

Usually combined with another antidiabetic drug(s) in type 2 DM
Do not stimulate insulin release, hence do not result in hypoglycemia

64
Q

Acarbose and miglitol inhibit?

The net result is?

A

inhibit the gastrointestinal enzymes α-glucosidase found on intestinal brush border, that converts dietary starch and other complex carbohydrates (disaccharides) into simple sugars (monosaccharides) which can be absorbed.

The net result is- they delay the absorption of glucose after meals (decrease postprandial hyperglycemia)

65
Q

Alpha glucosidase inhibitors ADR

A
GI effects (most common ***)
Release of gas (flatulence- most embarrassing), abdominal bloating, abdominal cramps and diarrhea
66
Q

Alpha glucosidase inhibitors contraindications

A

patients with chronic intestinal diseases, inflammatory bowel disease, colonic ulceration or intestinal obstruction

67
Q

Endogenous human incretins, such as______ and ______, are released from the _____ and enhance ______ secretion

A

Endogenous human incretins, such as glucagon-like-peptide-1 (GLP-1) and Glucose dependent insulinotropic polypeptide (GIP), are released from the gut and enhance insulin secretion

68
Q

Exenatide *
Liraglutide *
Albiglutide
Dulaglutide

A

GLP-1 analog

All of the GLP-1 receptor agonists may increase the risk of pancreatitis.***

69
Q

Sitagliptin
Saxagliptin
Linagliptin
Alogliptin

A

Dipeptidyl peptidase-4 (DPP-4) inhibitors: Oral)

70
Q

Exenatide -
ADR
Dose
Causes

A

Causes glucose dependent insulin release- Less hypoglycemia

given s.c. WEEKLY before meals.
marketed as pen which delivers 5 and10 μg.

Adverse effects: GI disturbances: Nausea, vomiting, diarrhea
Weight loss

71
Q

Liraglutide
Causes?
Given?

A

Causes glucose dependent insulin release- Less hypoglycemia

Is given as s.c. injection once DAILY.
marketed as pen that delivers 0.6, 1.2 and 1.8 mg of drug.

started with low dose for the initiation of therapy and dose escalated based on clinical response

Decreases appetite, causes nausea and vomiting and can also decrease body weight.

72
Q

Dipeptidyl Peptidase-4 (DPP-4) inhibitors prevent the breakdown of?

A

incretins like glucagon-like-peptide-1 (GLP-1) and Glucose dependent insulinotropic polypeptide (GIP), and lead to an increase in insulin secretion and decrease in glucagon level

73
Q

DPP-4 inhibitors are used alone or in combo with?

A

combination with other oral antidiabetic agents (such as metformin or thiazolidinedione or Insulin) for treatment of type-2 DM.

Lower HbA1c level by 0.4-1% points

The benefit is their lower adverse-effects (No hypoglycemia, do not cause weight gain),

74
Q

DPP-4 inhibitors ADR

A

Nasopharyngitis, upper respiratory infections, and headaches.

Acute pancreatitis (fatal and nonfatal)

Severe allergic and hypersensitivity reactions.

75
Q

Amylin

A

also called ‘islet amyloid polypeptide’ (IAPP)

Produced by pancreatic β-cells and acts in the brain to reduce glucagon secretion from α cells, delays gastric emptying, promotes satiety and retards glucose absorption.

76
Q

Pramlintide

A

synthetic amylin analog

exerts a centrally mediated anorectic effect.

used as adjuvant to meal time insulin injection (s.c.) to
suppress the glycemic peak in both type 1 and type 2 diabetics.

Reduction in body weight is an additional benefit

77
Q

Pramlintide:

S.C. injection administered?
With pramlintide, the dose of rapid-or short-acting insulin should be ?
Pramlintide must not be mixed in the same syringe with?

A

S.C. injection administered prior to meals.
With pramlintide, the dose of rapid-or short-acting insulin should be decreased by 50 %
Pramlintide must not be mixed in the same syringe with any insulin preparation.

78
Q

Pramlintide ADR

A

mainly gastrointestinal: nausea, anorexia, and vomiting.
Hypoglycemia

Should not be given to patients with diabetic gastroparesis (delayed stomach emptying), cresol hypersensitivity, or a history of hypoglycemic unawareness.

79
Q

SGLT-2 inhibitors

A

Practically all the glucose filtered at the glomerulus is reabsorbed (90%) in the proximal tubules. The major transporter which accomplishes this is SGLT-2

SGLT-2 inhibition induces glycosuria and lowers blood glucose in type 2 DM

Urinary loss of 50 to 80 grams of blood glucose per day

Loss of water and Na+ leads to a decrease in blood pressure, as well as weight loss.**

80
Q

Canagliflozin, Dapagliflozin, Empagliflozin, ertugliflozin

A

Used alone or in combination with other oral agents or insulin

In monotherapy, reduce HbA1c by 0.5%-1.0%

Do not cause hypoglycemia

Decrease in blood pressure, as well as body weight (2–5 kg)

Increased dehydration, UTI, vaginal mycotic infections

Increased frequency of DKA (in type-1 patients- off label use)

Increased LDL cholesterol levels.

Lower incidence of cardiovascular events (deaths, MI, strokes)

Higher rates of breast cancer (dapagliflozin)

Contraindicated in patients with renal failure

81
Q
Effect on BW and risk of hypoglycaemia in the following
Sulfonylureas
Meglitinides
Metformin
Thiazolidinediones
DPP-4 Inhibitors
SGLT-2 inhibitors
A

Sulfonylureas
BW↑↑
Hypogly↑↑

Meglitinides
BW↑
hypogly↑

Metformin
BW↓
hypogly ─

Thiazolidinediones
bw↑
hypogly↑

DPP-4 Inhibitors
BW─
hypo gly─

SGLT-2 inhibitors
BW↓
hypo gly─